Anti-Angiogenic Gene Therapy for Prostate Cancer
Final rept. 1 Apr 2003-30 Sep 2006
ALABAMA UNIV IN BIRMINGHAM
Pagination or Media Count:
In work supported by this funding, we produced high-titer recombinant AAV vectors encoding mouse endostatin and angiostatin, and human osteoprotegerin established TRAMP mouse breeding colony, and performed in vitro and in vivo studies to determine the effects of anti-angiogenic therapy at two different stages of prostate cancer progression. Additionally, we constructed rAAV encoding human OPG, produced high-titer virus and validated the biological efficacy of the vector encoded protein in inhibiting osteoclastogenesis in vitro. Continuation of the ongoing studies in the next few months will conclude these studies on therapeutic effects of anti-angiogenic gene therapy using adeno-associated virus in prostate cancer growth and metastasis.
- Medicine and Medical Research